Recent Advances in TransplantationCase reportTotal Artificial Heart as Bridge to Heart Transplantation in Chagas Cardiomyopathy: Case Report
Section snippets
Case Report
A 53-year-old woman (body surface area [BSA] 1.61 m2) had a dilated cardiomyopathy, HF, ventricular ectopy, prior pacemaker-cardioverter-defibrillator placement, atrial fibrillation, hypothyroidism, hypertension, hyperlipidemia, and diabetes. The patient was born in a country in Central America where CD was endemic, and immigrated to the United States. She developed decompensated HF. Serologies (immunoglobulin [Ig]G) for T cruzi were positive in July 2011 (>1:512) and October 2012.
The patient
Discussion
CD is a major cause of end-stage cardiomyopathy in Central and South America, and CC is the third leading indication for HTx in Brazil [8]. This cause of cardiomyopathy is having a serious economic impact on the United States, Europe, and other areas outside of Central and South America. In a 2009 publication, it was estimated that there were 300,000 persons with chronic CD in the United States, resulting in 30,000–45,000 cases of CC [9]. The cost of treatment in the United States is estimated
References (15)
- et al.
Heart transplantation for Chagas cardiomyopathy in the United States
Am J Transplant
(2013) - et al.
Chagas disease
Lancet
(2010) - et al.
Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas' heart disease
Int J Cardiol
(2005) - et al.
Screening and treatment of chagas disease in organ transplant recipients in the United States: recommendations from the chagas in transplant working group
Am J Transplant
(2011) - et al.
Implantation technique for the CardioWest total artificial heart
Ann Thorac Surg
(1999) - et al.
Antithymocyte globulin induction therapy adjusted for immunologic risk after heart transplantation
Transplant Proc
(2013) - et al.
Heart transplantation in 107 cases of Chagas' disease
Transplant Proc
(2011)
Cited by (0)
No funding was provided for this study. F. Arabia, MD, is a trainer for Syncardia System. The other authors have no conflicts of interest to disclose.